Online citations, reference lists, and bibliographies.
← Back to Search

Retreatment With Pemetrexed-based Chemotherapy In Patients With Malignant Pleural Mesothelioma.

G. Ceresoli, P. Zucali, F. De Vincenzo, L. Gianoncelli, M. Simonelli, E. Lorenzi, Cristina Ripa, L. Giordano, A. Santoro
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The role of second-line therapy in patients with malignant pleural mesothelioma (MPM) progressing after first-line pemetrexed-based chemotherapy (PBC) is currently undefined. Recent case series have suggested a possible role of re-treatment with PBC. In this observational study, the activity and safety of this therapeutic option was assessed in a consecutive series of cases. Patients with complete response (CR), partial response (PR) or stable disease (SD) lasting for at least 3 months after first-line PBC were retreated with PBC, either as second-line (2L) or further-line (>2L) therapy. Descriptive analyses of progression-free survival (PFS), overall survival (OS), response rate and toxicity are reported. Between October 2004 and July 2009, 31 patients (21 males and 10 females) received re-treatment with PBC as 2L (18 patients) or beyond 2L therapy (13 patients). Median age was 65 years (range 37-81). Fifteen patients were re-treated with pemetrexed alone, and 16 with a pemetrexed/platinum combination. An objective response was achieved in 6 patients (one CR and 5 PRs), for a response rate of 19%. Nine patients (29%) had SD after treatment. Overall, the disease control rate (DCR) was 48%. Median PFS and overall survival (OS) after re-treatment with PBC were 3.8 months and 10.5 months, respectively. PFS and OS after re-treatment with PBC were correlated with PFS achieved after first-line PBC (FL-PFS). Patients with a FL-PFS >12 months had a median PFS after re-treatment of 5.5 months, while patients with a FL-PFS ≤12 months had a median PFS after re-treatment of 2.5 months; no patient in this group was progression-free at 1 year. Toxicity was mild, with grade 3 or 4 hematological toxicity occurring in 9.7% of patients. In conclusion, re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC. Further prospective evaluation of this therapeutic option is warranted.
This paper references
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1053/J.SEMINONCOL.2006.03.012
Management of platinum-sensitive recurrent ovarian cancer.
J. Pfisterer (2006)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1016/j.clon.2010.01.009
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
J. Steer (2010)
10.1093/annonc/mdq253
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma.
P. Zucali (2010)
10.1016/S0190-9622(03)02155-8
Conflict of interest statement.
M. Franzblau (2003)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/0197-2456(96)00075-X
A note on quantifying follow-up in studies of failure time.
M. Schemper (1996)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1200/JCO.2007.25.18_SUPPL.18198
Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma
M. Serke (2007)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/J.LUNGCAN.2007.08.031
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
A. Razak (2008)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1159/000180580
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft Dw (1976)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1007/s10147-010-0064-7
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed
Hidetoshi Hayashi (2010)



This paper is referenced by
10.1097/JTO.0000000000000198
Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma
G. Pasello (2014)
10.1186/s12885-015-1881-x
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
Christine Raynaud (2015)
10.4161/cbt.22622
Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer
Sarah L. Suchy (2013)
10.1016/j.ctrv.2012.12.005
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
A LOCALIZED CONTROLLED DELIVERY SYSTEM UTILIZING A BLOCK COPOLYMER TO IMPROVE THE CURRENT PARADIGM OF CHEMOTHERAPY
Jason Olbrich (2013)
10.1097/MD.0000000000003351
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma
Xu-quan Jing (2016)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
on Novel Therapies
Andrew R. Haas (2013)
10.4155/CLI.11.72
Treatment of malignant pleural mesothelioma: current status and future directions
Paolo Andrea Zucali (2011)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.1016/j.cytogfr.2017.07.003
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
Luana Calabrò (2017)
10.1111/j.1759-7714.2012.00138.x
Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience
T. Okamoto (2013)
10.1136/esmoopen-2019-000669
How I treat malignant pleural mesothelioma
G. Viscardi (2020)
10.1007/s13665-012-0010-4
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
Réintroduction d’un traitement médicamenteux (chimiothérapie ou inhibiteur de récepteur à tyrosine kinase) dans les cancers bronchiques non à petites cellules : étude rétrospective monocentrique
X. Mignard (2017)
10.1007/978-3-030-33832-9_20
The Formidable Metamorphosis of the Salamander’s Wool: Asbestos from Eternal Material to Awful Pathologies
Lory Santarelli (2020)
10.1016/s1470-2045(19)30642-4
Tumour Treating Fields for mesothelioma: controversy versus opportunity.
D. A. Fennell (2019)
10.1007/s11864-011-0152-6
Chemotherapy for Malignant Pleural Mesothelioma
Linda L. Garland (2011)
10.1186/1756-0500-5-482
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
Giovanni Luca Ceresoli (2014)
10.1002/ccr3.1775
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
F. Grosso (2018)
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
N. Nasreen (2012)
10.5301/tj.5000364
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
Domenico Galetta (2016)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Giovanni Luca Ceresoli (2019)
10.1007/s11864-019-0616-7
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
V. Noia (2019)
10.1016/j.ctrv.2015.10.006
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Giovanni Luca Ceresoli (2015)
10.7314/APJCP.2014.15.21.9165
Caring for patients with malignant pleural mesothelioma in Japan: evaluation of a Palliative Care Educational Program.
Yasuko Nagamatsu (2014)
10.1159/000507816
Rechallenge Strategy in Cancer Therapy
Ekaterina Hanovich (2020)
10.1016/j.ctrv.2014.10.007
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar